# Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

> **NCT04993404** · PHASE1 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Insufficiency
- Healthy Subjects

## Interventions

- **DRUG:** Jaktinib Hydrochloride Tablets

## Key facts

- **NCT ID:** NCT04993404
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-27
- **Primary completion:** 2022-09-19
- **Final completion:** 2022-09-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993404, "Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04993404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*